Vesigen Therapeutics Announces Presentations at the American Society of Gene and Cell Therapy 26th Annual Meeting

CAMBRIDGE, Mass., May 2, 2023 /Business Wire/ — Vesigen Therapeutics, Inc., a biotechnology company developing a novel non-viral delivery platform ...

Vesigen Therapeutics Awarded Grant from Friedreich’s Ataxia Research Alliance (FARA) to Develop a Targeted Genome Editing Therapeutic Strategy

CAMBRIDGE, Mass., March 14, 2023 /Business Wire/ — Vesigen Therapeutics, Inc., a biotechnology company developing targeted therapies by engineering a ...

Vesigen Therapeutics, Inc. Announces Expansion of Scientific Advisory Board

CAMBRIDGE, Mass., February 7, 2023 /Business Wire/ — Vesigen Therapeutics, Inc., a biotechnology company developing transformative therapeutics by engineering naturally ...

Vesigen Therapeutics Names Rakhshita Dhar to Board of Directors

CAMBRIDGE, Mass., January 30, 2023 /Business Wire/ — Vesigen Therapeutics, Inc., a biotechnology company developing transformative therapeutics by engineering naturally ...

Vesigen Therapeutics Appoints Paulash Mohsen as Chief Executive Officer

CAMBRIDGE, Mass., Apr. 11, 2022 /Business Wire/ — Vesigen Therapeutics, Inc., a biotechnology company pioneering a novel extracellular vesicle delivery ...

Vesigen Therapeutics Presents at 3rd Exosome-Based Therapeutic Development Summit: Expanding the Therapeutic Boundaries of Exosomes

CAMBRIDGE, Mass., Nov. 16, 2021 /Business Wire/ — Vesigen Therapeutics, Inc., a biotechnology company pioneering a novel extracellular vesicle non-viral ...

LinkeIn Twitter